DOI: /ijasbt.v1i ISSN This paper can be downloaded online at
|
|
- Mervyn Hall
- 5 years ago
- Views:
Transcription
1 HK Tamang et al. (2013). Int J Appl Sci Biotechnol, Vol. 1(3): DOI: /ijasbt.v1i ISSN
2 DOI: /ijasbt.v1i Research Article International Journal of Applied Sciences and Biotechnology ISSN: SERUM LIPOPROTEIN (A) CONCENTRATION IS A BETTER PREDICTOR OF MYOCARDIAL INFARCTION THAN TRADITIONAL LIPID PROFILE AND LIPID RATIOS Abstract HK Tamang 1*, U Timilsina 2, KP Singh 3, R Shrestha 4, K Bist 4, L Maharjan 4 and S Shakya 4 1 Department of Biochemistry, Kantipur Dental College Teaching Hospital, Kathmandu, Nepal 2 Department of Medical Laboratory Technology, Kantipur Academy of Health Science, Kathmandu, Nepal 3 Department of Biochemistry, Institute of Medicine (TUTH), Kathmandu, Nepal 4 Department of Laboratory Medicine, Nobel College, Kathmandu, Nepal Corresponding author helosha@gmail.com Background- Lipoprotein (a) is a variant form of Low Density Lipoprotein (LDL) which comprises of an LDL like particle in which apo B-100 is firmly linked to apo-a glycoprotein. A large number of genetic and epidemiologic studies have identified Lipoprotein(a) as a risk factor for atherosclerotic diseases such as coronary heart disease and stroke. Based on our knowledge, this is the first study comparing Lipoprotein(a) with lipid profile and lipid ratios in Nepal. Aim & Objective- To compare the serum Lipoprotein(a) and Lipid panel concentrations in myocardial infarction patients and normal healthy control subjects. Materials & Methods- Study was carried out in 45 myocardial infarction patients as cases and 45 healthy subjects as controls. Lipoprotein(a) and Lipid profile tests were measured in serum using HumaStar 600 fully automated analyzer, Human, Germany. Results- Mean serum Lipoprotein(a) concentration in myocardial infarction group was significantly higher as compared to healthy controls. Lipid panel assays were not statistically significant among the groups. Conclusion- Our study revealed that myocardial infarction patients have elevated levels of serum Lipoprotein(a) as compared to healthy subjects. High concentration of serum Lipoprotein(a) is strongly associated with the risk of coronary heart disease. Keywords: - Lipoprotein(a), low density lipoprotein, myocardial infarction, lipid panel Introduction Lipoprotein(a) [Lp(a)], a genetically determined lipoprotein is composed of Low Density Lipoprotein (LDL) particle whose apolipoprotein B is bound to a plasminogen-like glycoprotein named apolipoprotein(a) (Utermann et al., 2001). Apolipoprotein(a), a member of plasminogenprothrombin family is found to interfere with the action of plasminogen and promotes thrombosis (Cobbaert et al., 1997). The prothrombotic nature of Lp(a) is supported by the studies that have shown the significant association of hyper-lp(a) and venous thrombosis (Sofi et al., 2007) and atherogenesis (Scanu et al., 1991). Coronary thrombosis formation is nowadays regarded as the most important cause of Acute Myocardial Infarction (AMI) (DeWood et al., 1980). Different studies have established Lp(a) as the independent risk factor for the development of atherosclerosis, genesis of AMI (Nguyen et al., 1997) and cerebrovascular diseases (Schwartzman et al., 1998). Serum Lp(a) is found to be higher in south Asians compared with Caucasians (Reddy et al., 1992) which is again confirmed by the finding that south Indian living in Britain had higher Lp(a) value than that of the white Europeans (Bhatnagar et al., 1995). These findings parallel with the increasing risk for myocardial infarction and cardiovascular death in migrants of south Asians than in other ethnic groups (Tuomilehto et al., 1984). Considering the role of Lp(a) in evolution of Acute Myocardial Infarction (AMI) and increasing burden of Cardiovascular Disease in south Asians we in our present study tried to investigate the predictive value of Lp(a) for AMI compared with traditional Lipid panel and ratios. Materials and Methods Study population- In this study a total number of 90 participants were included. 45 myocardial infarction (MI) positive participants (cases) admitted at Sahid Gangalal National Heart Center, Bansbari, Kathmandu, Nepal
3 and equal number of healthy participants (controls) aged above 30 years from Imadole and Gwarko communities of Lalitpur, Nepal were recruited. Patients with myocardial infarction were considered for our study after the confirmative diagnosis done by the cardiologist based on the findings of Electrocardiogram (ECG) and raised cardiac enzymes (Creatine Kinase MB, Lactate Dehydrogenase (LDH), Serum Glutarate Pyruvate Transminase(SGPT), Serum Glutarate Oxaloacetate Transaminase (SGOT) and Troponin I). All the participants except cases were asked for the history of diabetes, hormonal disorders, liver diseases, renal diseases and other chronic diseases. Those suspected of any disorders as indicated above were excluded. Sample Collection- After an overnight fast of at least 12 hours, blood samples were collected from the ante-cubital vein of each participant. Samples were collected in plain vials, allowed to clot, centrifuged at 3000rpm for 10 minutes and serum separated. Separated serum samples were preserved at -20 o C until assays were run. Biochemical Analysis- The lipid profile was done using CHOD-PAP method (Systemic Reagent for Humastar 600, Human, Germany). The Low Density Lipoprotein (LDL) was calculated using the Friedewald Formula (Friedewald et al., 1972). All the biochemical tests were run in the fully autoanalyzer (Humastar 600, Human, Germany). The serodos and serodos plus were used as the quality control samples and autocal as the standard to calibrate the tests. Both internal and external quality assurance tools were employed routinely to ensure the quality of test results. The Lp(a) concentration was measured using DRG ELISA Total Human Lipoprotein (a) (EIA- 4406), DRG International Inc., USA. The dynamic range of the Lp(a) ELISA assay kit was 3 µg/dl-405µg/dl. Ethical Clearance- Ethical clearance for the study was taken from Nepal Health Research Council, Nepal as per the Helsinki declaration of Statistical Analysis- All the statistical analysis were done using IBM SPSS Statistics (version 19) software. All tests of statistical significance were two sided with 95% confidence intervals (CI). Results A total of 90 subjects including equal numbers of MI cases and healthy normal controls were recruited in the study. The demographics of the study population are presented in Table-1. Plasma lipid profiles and Lipoprotein(a) of the groups are shown in Table-2. Lipid profile parameters were similar among the groups except for serum HDL Cholesterol which was significantly higher in normal controls (p= 0.026). Serum lipoprotein(a) value was significantly higher in MI cases (Figure-1) in comparison to the controls (p=0.004). Table 1- Demographics of study population MI Cases (n=45) Normal Controls (n=45) Sex Male Female N % N % Age (inyears) 54.51± ±10.81 N= number of subjects, n= population size
4 Table 2- Lipid panel parameters and Lp(a) levels of study population Analyte MI Cases Normal Controls T Test P value Total Cholesterol (TC) (mmole/l) 4.314± ± Triglyceride (TG) (mmole/l) 1.793± ± HDL Cholesterol (mmole/l) 1.008± ± * LDL Cholesterol (mmole/l) 2.452± ± TC /HDL Ratio 4.288± ± LDL/ HDL Ratio 2.485± ± Non HDL Cholesterol (mmole/l) 3.288± ± Lp(a) (µg/dl) ± ± ** *Statistically significant **Statistically highly significant Fig. 1- Distribution of serum Lp(a) levels among the study groups Discussion Findings of this study showed no significant differences in Total Cholesterol (TC), Triglycerides (TG), LDL Cholesterol (LDL-C), TC/HDL ratio, LDL/HDL ratio and Non HDL-Cholesterol among the groups. Rather it showed the significant differences in Lp(a) level and HDL-C level among the group. Woo et al., (1993) observed higher mean TC, LDL-C and TG as well as lower mean HDL-C in AMI patients; high HDL-C was among the protective factors. Similarly Kumar et al., 2009 observed significantly higher TC and TG levels and lower HDL-C levels in AMI patients. Though in our study, the mean TC, TG, LDL- C, TC/HDL, LDL/HDL and non HDL-C were higher in AMI patients than that found in healthy participant, they were statistically not significant. In line with our findings, Lehto et al., 1993 did not find any difference in mean serum TC levels between the AMI patients and controls. The risk of AMI was associated with an increase in LDL-C and a decrease in HDL-C in both Asians and non-asians (Karthikeyan et al., 2009). Lower concentrations of serum HDL-C and higher
5 serum TG were found to be independent risk factors while serum LDL-C was not associated with AMI (Tokuda, 2005). Though different studies have shown lipid profile and lipid ratio to be promising in assessing the cardiovascular risk, there are some contradictory findings as mentioned above. Significantly higher value of Lp(a) and significantly lower value of HDL-C in AMI patients than in healthy participants indicate that Lp(a) is much better predictor of AMI than traditional lipid profile and lipid ratios. Conclusion Nowadays homocystein, hs-crp, Apo B/Apo A1 ratio, Lp(a) and other emerging risk factors are considered to be superior cardiovascular risk assessment tools. Our study also indicated that Lp(a) can be the better predictor of AMI. Moreover, for lipid profile patient preparation is required (Patients are required to be on at least 12 hours fast). In addition, Friedwald formula for calculating LDL-C is not valid if TG level is more than 4.2 mmol/l (450 mg/dl). Lp(a) on other hand is genetically determined and it doesn t fluctuate with diet. Taking all these in consideration we from the current study would like to project Lp(a) as the better predictor of AMI though there still remain some questions that limit its dissemination in clinical practice as mentioned by Pischon et al., The central question focuses on the cost-benefit relation associated with a change in the traditional clinical approach. References Bhatnagar D, Anand IS, Durrington PN, et al. (1995) Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 345: Cobbaert C, Jukema JW et al. (1997) Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. J. Am. Coll. Cardiol. 30: DeWood MA, Spores J, Notsuke R et al. (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303: Friedewald WT, Levy RI and Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18: Karthikeyan G, Teo KK, Islam S, et al. (2009) Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol.53: Kumar A, Nagtilak S, Sivakanesan R and Gunasekera S (2009) Cardiovascular risk factors in elderly normolipidemic acute myocardial infarct patients-a case controlled study from India. Southeast Asian J Trop Med Public Health.40: Lehto S, Palomaki P, Miettinen H, et al. (1993) Serum cholesterol and high density lipoprotein cholesterol distributions in patients with acute myocardial infarction and in the general population of Kuopio province, eastern Finland. J Intern Med. 233: Nguyen TT, Ellefson R, Hodge DO et al. (1997) Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9,936 men and women. Circulation 96: Pischon T, Girman CJ, Sacks FM, et al. (2005). Non-highdensity lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112: Reddy S and Sanders TAB (1992) Lipoprotein risk factors in vegetarian women of Indian descent are unrelated to dietary intake. Atherosclerosis 95: Scanu AM, Lawn RM and Berg K (1991) Lipoprotein(a) and atherosclerosis. Ann Intern Med. 115: Schwartzman RA, Cox ID, Poloniecki J et al. (1998) Elevated plasma lipoprotein(a) is associated with coronary artery diseases in patients with chronic stable angina pectoris. J Am Coll Cardiol. 31: Sofi F, Marcucci R et al. (2007) Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med. 120: Tokuda Y (2005) Risk factors for acute myocardial infarction among Okinawans. J Nutr Health Aging. 9: Tuomilehto J, Ram P, Eseroma R, et al. (1984) Cardiovascular diseases and diabetes mellitus in Fiji: analysis of mortality, morbidity and risk factors. Bull World Health Organ. 62: Utermann G (2001) Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds) The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill Publishing Co, Woo J, Ho SC, Wong SL, et al. (1993) Lipids, lipoproteins and other coronary risk factors in Chinese male survivors of myocardial infarction. Int J Cardiol. 39:
Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationIndian Journal of Basic & Applied Medical Research; December 2011: Issue-1, Vol.-1, P
Comprehensive levels of Serum Enzymes and Lipid Profile testing in MI and Stable Angina Subjects. K.Satya Narayana*, Dr.Anija Uchuru**, Dr.Ivvala Anand Shaker*, S.Saleem Basha*, K.Suresh Babu* *Dept of
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAssociation between Plasma Homocysteine Concentrations and Carotid Intima-Media Thickness in Patients with Coronary Artery Disease
Association between Plasma Homocysteine Concentrations and Carotid Intima-Media Thickness in Patients with Coronary Artery Disease ROXANA BUZAŞ, CORINA ŞERBAN, IOANA SUCEAVA, DANIEL LIGHEZAN University
More informationClinical Study of Lipid Profile Pattern in Acute Coronary Syndromes
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/359 Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes V Suresh Kumar, Madavaram Sreelatha Assistant
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationFriedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula
Friedewald formula 1 1 1,2 ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5 Friedewald formula Friedewald formula 2003 99 Friedewald formula Colorimetric method
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationPrediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal
Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Koju R, Gurung R, Pant P, Humagain S, Yogol CM, Koju A, Manandhar K, Karmacharya B, Bedi TRS Address for Correspondence:
More informationImpact of Chronicity on Lipid Profile of Type 2 Diabetics
Impact of Chronicity on Lipid Profile of Type 2 Diabetics Singh 1, Gurdeep & Kumar 2, Ashok 1 Ph.D. Research Scholar, Department of Sports Science, Punjabi University Patiala, India, Email: drgurdeep_sahni@yahoo.co.in
More informationASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS
ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS V Shanmugapriya, PK Mohanty, D Anil Kumar Department of Biochemistry, Vinayaka Missions Medical
More informationISCHEMIC HEART DISEASE: Role of Total Cholesterol: HDL C Ratio as an Important Indicator Compared to LDL C.
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 14, Number 1 (2018) pp. 13-17 Research India Publications http://www.ripublication.com ISCHEMIC HEART DISEASE: Role of Total
More informationEXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION
1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationAssociation of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions
ORIGINAL ARTICLE J Nepal Med Assoc 2011;51(184):157-63 Association of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions Shrestha R 1, Jha
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More information行政院國家科學委員會補助專題研究計畫成果報告
NSC892314B002270 898 1 907 31 9010 23 1 Molecular Study of Type III Hyperlipoproteinemia in Taiwan β β ε E Abstract β Type III hyperlipoproteinemia (type III HLP; familial dysbetalipoproteinemia ) is a
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationPattern of plasma lipoprotein (a) in Sudanese patients with coronary
Pattern of plasma lipoprotein (a) in Sudanese patients with coronary artery disease Mansour Eltahir Farah 1, Khairia Eltahir Abdullah 2, Huda HM Elhassan 3, Mohammed O EH Gadour 1, Mohammed Saeed Alkhaleefa
More informationCOMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI
COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI WITH TRADITIONAL LIPID MEASURES IN WOMEN DIAGNOSED WITH ACUTE CORNONARY SYNDROMES A PRELIMINARY REPORT. Magdalena Krintus, Katarzyna
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationReeju Manandhar, Chaofeng Sun. Original article
Original article Association of different blood parameters with the early patency of Infarct related artery in ST elevation Myocardial Infarction, a comparative analysis. Reeju Manandhar, Chaofeng Sun
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationReview of literature. Total Cholesterol (TC)
Total Cholesterol (TC) Kinosian B et al (1995) 56 observed in their study that TC was the better predictors of risk for coronary heart disease than LDL cholesterol. Peter W. F et al (1998) 77 showed that
More informationPattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus
Original Article Nepal Med Coll J 2012; 14(4): 278-282 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus A
More informationStudy of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri
Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.
More informationEFFICIENCY AND COST-EFFECTIVENESS OF DYSLIPIDEMIA SCREENING METHODS AMONG WORKERS IN BANGKOK
EFFICIENCY AND COST-EFFECTIVENESS OF DYSLIPIDEMIA SCREENING METHODS AMONG WORKERS IN BANGKOK Unchalee Sanguantrakul, Wiroj Jiamjarasrangsi and Thosporn Vimolket 1 Department of Preventive and Social Medicine,
More informationMartin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER
TAP TO GO BACK TO KIOSK MENU Seth S. Martin, M.D., M.H.S., Robert P. Giugliano, M.D., S.M., 2 Sabina A. Murphy, M.P.H., 2 Scott M. Wasserman, M.D., 3 Peter S. Background Evolocumab, a fully human monoclonal
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationLipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft; a cross sectional study
Bandara et al. BMC Cardiovascular Disorders (2016) 16:213 DOI 10.1186/s12872-016-0393-1 RESEARCH ARTICLE Open Access Lipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft;
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationBiomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease
Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationClinical study of Huxinkang tablet in treating unstable angina pectoris
ISSN : 0974-7435 Volume 10 Issue 17 BTAIJ, 10(17), 2014 [9538-9543] Clinical study of Huxinkang tablet in treating unstable angina pectoris Wang Guoqian 1, Yu Zhengke 2, Cheng Zhihong 2, Xie hongtu 3 1
More informationTina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk
Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk cobas modular platform Flexible configurations for tailormade solutions With the cobas modular platform (cobas
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 35 Last Review Status/Date: December 2014 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationCardiovascular Disease
Cardiovascular Disease Chapter 15 Introduction Cardiovascular disease (CVD) is the leading cause of death in the U.S. One American dies from CVD every 33 seconds Nearly half of all Americans will die from
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationIschemic Heart Disease
Ischemic Heart Disease Dr Rodney Itaki Lecturer Division of Pathology University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Consideration Results from partial
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationKeywords: Type 2 DM, lipid profile, metformin, glimepiride ABSTRACT
Human Journals Research Article September 2015 Vol.:4, Issue:2 All rights are reserved by K. Saravanan et al. Effects of Monotherapy and Combination Therapy Involving Metformin and Glimepiride on HbA1c
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 34 Last Review Status/Date: March 2016 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients
ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Novel Biomarkers in Risk Assessment and Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Novel Biomarkers in Risk Assessment and Management of Cardiovascular
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationAssociation of Major Modifiable Risk Factors Among Patients with Coronary Artery Disease - A Retrospective Analysis
Original Article Association of Major Modifiable Risk Factors Among Patients with Coronary Artery Disease - A Retrospective Analysis V Achari, AK Thakur Abstract Background : The relative importance of
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Policy Number: 2.04.65 Last Review: 1/2018 Origination: 1/2011 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(5): September-October 15 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Life Sciences Research Article!!! Received:
More informationYongyan Song 1, Yang Yang 2, Jingxiao Zhang 3, Yanmei Wang 3,4, Wenfeng He 3, Xiaoming Zhang 5, Jie Zhu 2 and Zhan Lu 3*
Song et al. Lipids in Health and Disease (2015) 14:150 DOI 10.1186/s12944-015-0155-6 RESEARCH Open Access The apob100/apoai ratio is independently associated with the severity of coronary heart disease:
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationEFFECT OF BIOCHEMICAL PARAMETERS SHOWING ATHEROGENICITY IN TYPE 2 DIABETIC NEPHROPATHY
EFFECT OF BIOCHEMICAL PARAMETERS SHOWING ATHEROGENICITY IN TYPE 2 DIABETIC NEPHROPATHY *G. Raja and Ivvala Anand Shaker * Department of Biochemistry, Melmaruvathur Adhiparasakthi Institute of Medical Sciences
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationLipid Profile Analysis of Aircrew
Original Article Lipid Profile Analysis of Aircrew Sampath S *, Richa + ABSTRACT Most laboratories including all our Armed Forces Centers, estimate Low Density Lipoproteins Cholestorol (LDL-C) levels with
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More informationASSESSMENT OF INSULIN RESISTANCE AND Apo B / Apo A1 RATIO IN TYPE II DIABETES PATIENTS
ORIGINAL ARTICLE ASSESSMENT OF INSULIN RESISTANCE AND Apo B / Apo A RATIO IN TYPE II DIABETES PATIENTS 2 3 RP.Sathvika, Philips Abraham, R.Sudha, Evangeline Jones Background: Insulin resistance (IR) is
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationAcute coronary syndrome (ACS) is a major cause of morbidity and mortality
32 Journal of the association of physicians of india vol 62 published on 1st of every month 1st july, 2014 Original Article Novel Atherosclerotic Risk Factors and Angiographic Profile of Young Gujarati
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Subject: Novel Biomarkers in Risk Assessment and Page: 1 of 31 Last Review Status/Date: March 2017 Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Description Numerous lipid
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationImpact of metabolic syndrome on hospital in acute myocardial infarction patients
Original Article Impact of metabolic syndrome on hospital in acute myocardial infarction patients Pravin Rohidasrao Bhagat 1*, Shubhangi Virbhadra Swami 2 outcomes { 1 Assistant Professor, Department of
More informationAnalysis of frequency of increased waist to hip ratio in patients of acute myocardial infarction
International Journal of Advanced Biotechnology and Research (IJABR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-10, Issue-2, 2019, pp184-188 http://www.bipublication.com Research Article Analysis of frequency
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3701 CV Health Plus Genomics - Plasma, Serum & Buccal Swab Methodology: Chemiluminescent, Enzymatic, Immunoturbidimetric, NMR and PCR Lipid Markers Cholesterol LDL-
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationISSN: X Impact factor: 4.295
ISSN: 2454-132X Impact factor: 4.295 (Volume3, Issue1) Available online at: www.ijariit.com A Cross Sectional Study for Evaluation of Association between Hypertensive Retinopathy with Serum Lipid Profile
More informationPOST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) Term-End Examination June, 2015
No. of Printed Pages : 20 MCC-006 POST GRADUATE DIPLOMA IN CLINICAL 0 CARDIOLOGY (PGDCC) Term-End Examination June, 2015 MCC-006 : CARDIO VASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note :
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationREVIEW ARTICLE REVIEW ARTICLE. Fasting versus non-fasting Lipid profile in the clinical practice
REVIEW ARTICLE REVIEW ARTICLE DOI: http://doi.org/10.4038/sjdem.v8i2.7355 Fasting versus non-fasting Lipid profile in the clinical practice Umakanth M Faculty of Health care sciences, Eastern university-sri
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More information